Date: 2016-04-12
Type of information: Fundraising
Company: Forbion Capital Partners (The Netherlands)
Investors: European Investment Fund (EIF) Dutch Venture Initiative (DVI), KfW (Germany) regional investment agencies, pension funds, insurance companies, leading European family offices, Charles River Laboratories (USA) Knight Therapeutics (Canada)
Amount: € 183 million
Funding type: fundraising
Planned used: Forbion Capital Fund III (FCF III) has an investment strategy similar to its predecessor fund, FCF II, aiming to invest the majority of the fund (around 70%) in Europe and the remainder in the US and Canada. The investment focus is on private companies developing novel drugs, medical devices and diagnostics for high, or even unmet, medical needs. The fund has already invested in seven promising portfolio companies, including Engene, Rigontec, Replimune, Autonomic Technologies Europe, Sanifit, Staten Biotech and Akarna. These companies cover a range of globally important disease areas including cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, and pain management.
Others: * On April 12, 2016, Forbion Capital Partners, a dedicated life sciences venture capital firm, today announced the final closing of its third main fund Forbion Capital Fund III (FCF III), raising a total of € 183 million (approx. $ 208 million). With this fundraising, Forbion secured both returning investors and further expanded its global investor base of high quality limited partners, to include the European Investment Fund (EIF) (also through the EIF’s ERP-EIF and LfA-EIF facilities), the Dutch Venture Initiative (DVI), Germany’s KfW development bank, various other regional investment agencies, pension funds, insurance companies, leading European family offices and two strategic investors: Charles River Laboratories and Knight Therapeutics. Alongside its three main funds, Forbion also manages several Co-Invest Funds (venture growth funds) and co-manages several earlier stage funds with BioGeneration Ventures. Forbion typically leads the investment syndicates it forms and has built a strong track record in recent years. With the close of FCF III, Forbion now manages well over € 700 million. In order to swiftly and effectively deploy the newly raised fund, Forbion’s investment team has been expanded with Matthias Falcenberg joining as an Analyst at Forbion’s operations in Munich, from the Max-Planck-Institute of Biochemistry.
Therapeutic area:
